ANIX Company Profile and Key Details

Q: Who are the executives of ANIX?

Dr. Pamela D. Garzone Ph.D.Chief Devel. Officer & Chair Breast Cancer Clinical Advisory BoardDr. Amit Kumar Ph.D.Chairman & Chief Executive OfficerMr. Michael J. Catelani CPA, MBAPres, Chief Operating Officer, Chief Financial Officer & Corporation Sec.Mr. John RoopSenior Vice President of Engineering

NASDAQ : ANIX

Anixa Biosciences

$2.70

0.11+4.25%

At Close 4:00 PM

66.08

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Anixa Biosciences, Inc. (ANIX) stock surged +4.25%, trading at $2.70 on NASDAQ, up from the previous close of $2.59. The stock opened at $2.64, fluctuating between $2.59 and $2.83 in the recent session.

Stock Snapshot

2.59

Prev. Close

90.53M

Market Cap

2.585

Day Low

-8.44

P/E Ratio

-0.32

EPS (TTM)

-0.21

Cash Flow per Share

2.64

Open

33.53M

Number of Shares

2.83

Day High

94.7%

Free Float in %

0.78

Book Value

131.6K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 25, 2026	2.64	2.83	2.56	2.70	132.68K
Mar 24, 2026	2.60	2.66	2.45	2.59	179.18K
Mar 23, 2026	2.72	2.84	2.52	2.61	115.94K
Mar 20, 2026	2.75	2.89	2.63	2.65	107.56K
Mar 19, 2026	2.75	2.79	2.68	2.77	82.19K
Mar 18, 2026	2.90	2.90	2.75	2.77	93.76K
Mar 17, 2026	2.93	2.94	2.84	2.89	32.33K
Mar 16, 2026	2.84	2.92	2.76	2.84	76.49K
Mar 13, 2026	2.90	2.93	2.81	2.83	67.71K
Mar 12, 2026	2.90	3.03	2.83	2.86	54.8K
Mar 11, 2026	2.98	3.01	2.85	2.94	47.64K
Mar 10, 2026	3.01	3.03	2.85	2.98	86.02K
Mar 09, 2026	2.88	3.05	2.83	2.98	128.48K
Mar 06, 2026	2.93	2.98	2.80	2.85	87.62K
Mar 03, 2026	2.91	2.97	2.78	2.83	157.67K
Mar 02, 2026	2.88	3.02	2.87	2.96	124.04K
Feb 27, 2026	3.02	3.02	2.91	2.98	95.03K
Feb 26, 2026	3.00	3.04	2.94	3.04	48.38K
Feb 25, 2026	3.02	3.05	2.94	3.02	83.17K
Feb 24, 2026	2.94	3.02	2.89	3.00	154.9K

Contact Details

San Jose, CA 95118

United States

https://www.anixa.com 408 708 9808

About Company

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Stock Peers

REGN

7.78+1.05%

Regeneron Pharmaceuticals, Inc.$749.47 ARGX

19.55+2.89%

argenx SE$697.05 UTHR

9.78+1.84%

United Therapeutics Corporation$541.60 MDGL

16.89+3.80%

Madrigal Pharmaceuticals, Inc.$461.93 VRTX

6.35+1.42%

Vertex Pharmaceuticals Incorporated$454.97 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

20.65+6.70%

Alnylam Pharmaceuticals, Inc.$328.70 PRAX

17.27+5.86%

Praxis Precision Medicines, Inc.$311.92 KRYS

7.86+3.18%

Krystal Biotech, Inc.$254.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Anixa Biosciences, Inc. (NASDAQ:ANIX) closed at $2.70 USD, gaining $0.11 (4.25%) from the previous close of $2.59. The stock is currently mid-range between its 52-week high and low $2.33 and $5.46. With a market capitalization of about $90.53 million, Anixa Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.52). Key stats such as the average daily volume over the past year has been around 165.38 thousand shares, in line with its 52-week average. Headquartered in San Jose, CA, Anixa Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Amit Kumar, the company employs approximately 5 people and listed since October 07, 1983. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.

Technical Performance

ANIX has shown mixed momentum, losing -1.58% over the past week and -24.15% over the past quarter, though year-to-date performance is down -0.32%. Short-term trend indicators are bullishly aligned (SMA20 3.51%, SMA50 -2.49%, SMA200 -10.99%). The stock’s 14-day RSI is 50.63 (neutral), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.29% below its high and over 30.42% above its low. Average 10-day trading volume of 102.52 thousand shares is below the 3-month average of 166.17 thousand, indicating normal recent market interest.

Valuation Metrics

Anixa Biosciences, Inc. trades at a P/E ratio of -8.69, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.94 trading at moderately above to book value. The P/FCF stands at -13.14, also below market averages.

Dividend & Fair Value

Anixa Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.03. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Anixa Biosciences, Inc. generated EPS of -$0.34 over the past year. Five-year average earnings growth is 5.67%. Wall Street analysts project EPS growth of 1.14% annually over the next five years. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$15.62. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $7.00. The high target offers 270.37% upside. The low target suggests 159.26% downside. The mean target is $9.45. This offers 250.0% upside. Anixa Biosciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended September 10, 2025, missed forecasts by -30.0%. The prior quarter beat by -10.0%. Over the last six quarters, Apple has recorded several small beats. These include -9.09% in June 04, 2024.

Shareholding & Insider Activity

Anixa Biosciences, Inc. has 33.53 million shares outstanding. The public float is 31.72 million shares, elevated short interest at 3.63% of float. This equals 1.15 million shares. The short ratio is 12.79 days. Institutional investors hold 17.64% of the float. Insiders own 5.41%. Titterton Lewis H jr holds 953.33 thousand shares, KUMAR AMIT has 579.92 thousand shares and JOHNSON BRUCE F has 419.12 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Anixa Biosciences has not generated any revenue. Returns are negative, with ROA at -42.81% and ROE at -44.90%.
On valuation metrics, Anixa Biosciences trades at a P/E of -8.69, P/S of 0.00 and P/B of 5.94. The current ratio is 12.18 and quick ratio is 12.18. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2843.16 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -35.64.

Quarterly Financial Highlights

For the quarter ended Oct 31, 2025, Anixa Biosciences posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $36.00K (margin 0.00%). Operating income was - $11.70M (margin 0.0%). Net income was- $10.93M (EPS - $0.34).
The company ended the quarter with $23.84M in cash and short-term investments, a total debt of $175.00K, and net debt of - $740.00K. Total assets were $25.52M, with equity of $23.37M. Financials further reflected weakness, with operating cash flow of - $6.21M, free cash flow of - $6.21M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Anixa Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.37%, with price expected at $2.42 by April 08, 2026, within a range of $2.34 to $2.51 3-Month Outlook: Projected fall of -13.33%, reaching $2.34 by June 22, 2026, with a range of $2.19 to $2.47. 1-Year Outlook: Projected gain of 96.67%, with price at $5.31 by March 25, 2027, within a range of $0.00 to $8.14.

Key Takeaways

Anixa Biosciences, Inc. (NASDAQ:ANIX) shares are flat -0.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Anixa Biosciences, Inc. trading at a premium to the broader market with a P/E of -8.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.91, suggesting 267.04% upside. Our AI forecast model points to short-term weakness (-10.37% over two weeks), a medium-term fall (-13.33% over three months), and a longer-term gain (96.67% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Anixa Biosciences, Inc. (ANIX) stock price?

Anixa Biosciences, Inc. (NASDAQ: ANIX) stock price is $2.70 in the last trading session. During the trading session, ANIX stock reached the peak price of $2.83 while $2.59 was the lowest point it dropped to. The percentage change in ANIX stock occurred in the recent session was 4.25% while the dollar amount for the price change in ANIX stock was $0.11.

ANIX's industry and sector of operation?

The NASDAQ listed ANIX is part of Biotechnology industry that operates in the broader Healthcare sector. Anixa Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ANIX?

Dr. Pamela D. Garzone Ph.D.
Chief Devel. Officer & Chair Breast Cancer Clinical Advisory Board
Dr. Amit Kumar Ph.D.
Chairman & Chief Executive Officer
Mr. Michael J. Catelani CPA, MBA
Pres, Chief Operating Officer, Chief Financial Officer & Corporation Sec.
Mr. John Roop
Senior Vice President of Engineering

How ANIX did perform over past 52-week?

ANIX's closing price is 15.88% higher than its 52-week low of $2.33 where as its distance from 52-week high of $5.46 is -50.55%.

How many employees does ANIX have?

Number of ANIX employees currently stands at 5.

Link for ANIX official website?

Official Website of ANIX is: https://www.anixa.com

How do I contact ANIX?

ANIX could be contacted at phone 408 708 9808 and can also be accessed through its website. ANIX operates from 3150 Almaden Expressway, San Jose, CA 95118, United States.

How many shares of ANIX are traded daily?

ANIX stock volume for the day was 131.6K shares. The average number of ANIX shares traded daily for last 3 months was 165.38K.

What is the market cap of ANIX currently?

The market value of ANIX currently stands at $90.53M with its latest stock price at $2.70 and 33.53M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5
Beta	0.52
Sales or Revenue	$0.00
5Y Sales Change%	-0.893%
Fiscal Year Ends	October
Sector	Healthcare
Industry	Biotechnology

ANIX Company Profile and Key Details

Anixa Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook